Press Releases Video Library Careers
Bladder Cancer Breaking News | CG Oncology
Home News & Media Press Releases In the News Media Resources

PRESS RELEASES

  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2015
  • 2014
New Cretostimogene…
December 5, 2025
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
CG Oncology to Present…
November 25, 2025
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
CG Oncology Announces…
April 26, 2025
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association...
Host Conference Call…
April 24, 2025
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
CG Oncology to Participate…
March 31, 2025
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
CG Oncology Reports…
March 28, 2025
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
Cretostimogene Grenade…
March 24, 2025
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
CG Oncology Announces…
December 16, 2024
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces…
December 12, 2024
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces…
December 11, 2024
CG Oncology Announces Proposed Public Offering
Groundbreaking Creto…
December 5, 2024
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Present…
November 20, 2024
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
CG Oncology Reports…
November 12, 2024
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces…
November 11, 2024
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
CG Oncology to Unveil…
April 24, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
CG Oncology to Present…
March 28, 2024
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
CG Oncology Announces…
February 27, 2024
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
CG Oncology Announces…
January 30, 2024
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces…
January 24, 2024
CG Oncology Announces Pricing of Upsized Initial Public Offering
CG Oncology Receives…
December 5, 2023
CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Cretostimogene Grena…
November 30, 2023
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
CG Oncology Announces…
November 14, 2023
CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023
CG Oncology Announces…
September 5, 2023
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
CG Oncology Announces…
August 2, 2023
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline
CG Oncology Completes…
July 24, 2023
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with cretostimogene grenadenorepvec in BCG-Unresponsive High-Risk NMIBC
CG Oncology Announces…
May 3, 2023
CG Oncology Announces New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in BCG-Unresponsive NMIBC
New Phase 2 Data…
April 10, 2023
New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting
CG Oncology to Present …
December 27, 2022
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
CG Oncology Raises…
November 15, 2022
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
CG Oncology Presents…
November 10, 2022
CG Oncology Presents New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
CG Oncology to Present…
October 24, 2022
CG Oncology to Present New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC...
CG Oncology Presents…
June 4, 2022
CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CG Oncology Presents…
May 16, 2022
CG Oncology Presents Additional Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
CG Oncology Announces…
December 20, 2021
CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of cretostimogene grenadenorepvecin Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
CG Oncology Presents…
November 13, 2021
CG Oncology Presents Preliminary Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
CG Oncology to Present…
October 12, 2021
CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
CG Oncology and Roche…
September 22, 2021
CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy cretostimogene grenadenorepvec as Part of Novel Combination for Various Solid Tumor Indications
CG Oncology Announces…
September 9, 2021
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy cretostimogene grenadenorepvec in Combination with nivolumab in Metastatic Urothelial Cancer
CG Oncology Closes…
December 10, 2020
CG Oncology Closes $47 Million Series D Financing
CG Oncology Announces…
December 9, 2020
CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of cretostimogene grenadenorepvec, an Oncolytic Immunotherapy, in Combination with pembrolizumab for Non-Muscle-Invasive Bladder Cancer...
CG Oncology Announces…
November 12, 2020
CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy cretostimogene grenadenorepvec in Combination with nivolumab in Muscle-Invasive Bladder Cancer
CG Oncology Announces…
March 26, 2020
CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for cretostimogene grenadenorepvec in Japan and Other Asian Countries
$22 Million Series…
March 15, 2019
$22 Million Series C Financing
Clinical Trial Collaboration…
November 28, 2018
Clinical Trial Collaboration to Evaluate the Combination of cretostimogene grenadenorepvec and pembrolizumab in Bladder Cancer
Clinical Results…
May 15, 2017
Clinical Results at American Urological Association (AUA) Annual Meeting 2017
FDA Acceptance…
October 19, 2015
FDA Acceptance of a Phase I/II Clinical Trial Using cretostimogene grenadenorepvec Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer
Series B Investment…
August 5, 2015
Series B Investment for Pivotal and Combo Immunotherapy Trials
$13.57 Million in a Series…
July 30, 2014
$13.57 Million in a Series A Round of Financing to Accelerate Its Ongoing Phase II/III Clinical Trial for Bladder Cancer

CG ONCOLOGY IN THE NEWS

Selecting a link will open a new tab and take you to another website.

  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
CANCER NETWORK
March 25, 2025
Cretostimogene Grenadenorepvec Yields Sustained Antitumor Activity in NMIBC
UROLOGY TIMES
March 25, 2025
Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC
CURE
March 24, 2025
Cretostimogene Has Durable Response in BCG-Unresponsive Bladder Cancer
SCRIP
December 5, 2024
CG Oncology Is Building A Best-In-Class Profile in NMIBC
ENDPOINTS NEWS
December 5, 2024
CG Oncology’s bladder cancer treatment shows durability potential in Phase 3
REUTERS
December 5, 2024
Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer
NATURE MEDICINE
November 11, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
NATURE MEDICINE
June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
ONCLIVE
January 3, 2024
FDA Grants Fast Track, Breakthrough Therapy Designations to Cretostimogene Grenadenorepvec for NMIBC
PHARMACEUTICAL TECHNOLOGY
December 6, 2023
CG Oncology’s bladder cancer drug gets fast track to approval
SCIENCE
December 5, 2023
Tumor-killing viruses score rare success in late-stage trial Bladder cancer results suggest that after decades of failure, the viruses could finally reach their potential
UROTODAY
December 4, 2023
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
UROLOGY TIMES
November 30, 2023
Cretostimogene grenadenorepvec hits high complete response rate in NMIBC
ENDPOINTS NEWS
August 2, 2023
CG Oncology reels in $105M crossover for potential late 2024 bladder cancer drug filing
FORBES
August 2, 2023
CG Oncology, led by Forbes 30 Under 30 alum Arthur Kuan, wants to supplant the current treatment for a form of cancer that’s been virtually...
FIERCE BIOTECH
August 2, 2023
CG Oncology brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial
TARGETED ONCOLOGY
July 25, 2023
BOND-003 Study of Cretostimogene Grenadenorepvec in NMIBC Completes Enrollment
ENDPOINTS NEWS
May 24, 2023
Endpoints 20 under 40 – Arthur Kuan is featured
ONCOLOGY TUBE
May 23, 2023
Pembrolizumab combined with cretostimogene grenadenorepvec. How can this help patients with NMIBC? Roger Li
UROTODAY
May 11, 2023
Gene Therapy and Pembrolizumab in BCG-Unresponsive CIS-Containing Population: Updated Results, Efficacy, and Correlative Studies – Roger Li
MEDPAGE TODAY
May 3, 2023
‘Fantastic,’ ‘Terrific’ Results With Oncolytic Virus Combo for Bladder Cancer
ONCLIVE
April 29, 2023
Phase 2 Data Show Clinical Activity With cretostimogene grenadenorepvec Plus Pembrolizumab in NMIBC
ONCLIVE
April 29, 2023
Dr Li on the Use of cretostimogene grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive Non–muscle Invasive Bladder Cancer
MEDPAGETODAY
March 1, 2023
Emerging Therapies in Non-Muscle-Invasive Bladder Cancer
EVALUATE
February 2, 2023
A renewed push into early bladder cancer
BIOCENTURY
November 18, 2022
Oncolytic virus combinations move beyond checkpoint inhibitors
WALL STREET JOURNAL
November 15, 2022
Venture Capitalists Back CG Oncology’s Search for New Bladder Cancer Treatment
ENDPOINTS NEWS
November 15, 2022
Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out
UROLOGY TIMES
November 15, 2022
Combo of oncolytic immunotherapy and pembrolizumab continues to show promise in BCG-unresponsive NMIBC
ENDPOINTS NEWS
November 10, 2022
CG Oncology spotlights oncolytic virus combo data ahead of full readout due next year
INSIDER
September 13, 2022
Arthur Kuan Featured in 30 Leaders under 40 Changing Healthcare in 2022
CANCER NETWORK
June 23, 2022
Roger Li, MD, Provides In-Depth Description of Cretostimogene Grenadenorepvec Mechanism of Action in Bladder Cancer
TARGETED ONCOLOGY
June 21, 2022
Cretostimogene Grenadenorepvec Provides Durable Responses in Certain Patients with Non-Muscle Invasive Bladder Cancer
BIOSPACE
June 6, 2022
CG Oncology Teams with Merck, BMS for Positive Bladder Cancer Results
ENDPOINTS NEWS
June 6, 2022
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
ARGETED ONCOLOGY
May 16, 2022
Results of Cretostimogene Grenadenorepvec Combined With Pembrolizumab in BCG-Unresponsive NMIBC
TARGETED ONCOLOGY
April 24, 2022
Cretostimogene Grenadenorepvec With Pembrolizumab Shows Encouraging Results in BCG-Unresponsive NMIBC
CANCER NETWORK
April 13, 2022
Oncolytic Adenovirus, Cretostimogene Grenadenorepvec, Plus Pembrolizumab Shows Promise in BCG-Unresponsive NMIBC
BIOSPACE
April 5, 2022
CG Oncology’s Bladder Cancer Therapy Impresses at AACR
ONCLIVE
November 29, 2021
Cretostimogene Grenadenorepvec Plus Pembrolizumab Shows Early Tolerability and Activity in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
CANCER NETWORK
November 23, 2021
Cretostimogene Grenadenorepvec Plus Pembrolizumab Yields Positive Preliminary Data in Non-Muscle Invasive Bladder Cancer
CLINICAL TRIALS ARENA
November 15, 2021
CG Oncology reports Phase II preliminary data on bladder cancer therapy
MEDCITY NEWS
August 23, 2021
CG Oncology CEO highlights biotech’s oncolytic immunotherapy for bladder cancer
CGT LIVE
August 4, 2021
Advantages of Cretostimogene Grenadenorepvec Over Standard Care for Non-Muscle Invasive Bladder Cancer
CGT LIVE
July 30, 2021
Cretostimogene Grenadenorepvec: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder Cancer
ORANGE COUNTY BUSINESS JOURNAL
December 20, 2020
Cancer Therapeutics Firm Reels in $47M
FIERCE BIOTECH
December 11, 2020
Oncolytic immunotherapy biotech CG Oncology nabs $47M round for late-stage cancer push
ENDPOINTS NEWS
December 11, 2020
CG Oncology nets $47M Series D for bladder cancer studies; Single-cell transcriptomic startup raises $24M launch cash
WSJ
December 10, 2020
Drugmaker CG Oncology Grabs $47 Million for Bladder Cancer Trials
BIOCOM CATALYST AWARD
December 8, 2020
Ten Life Science trailblazers under the age of 40 recognized across California: including Arthur Kuan, CEO, CG Oncology, Inc
FORBES
November 7, 2020
Forbes profile Arthur Kuan 30 under 30

You are leaving the CG Oncology website and we are not responsible for the content and maintenance of the site you are accessing.

MEDIA RESOURCES

Company Logos

Official CG Oncology logo image
CG Oncology logo with tagline “Attacking Bladder Cancer for a Better TomorrowTM” next

CG Oncology Corporate One Pager

Thumbnails of CG Oncology Corporate one-pager available for download

MECHANISM OF ACTION IMAGES

Thumbnail of a downloadable image of cretostimogene grenadenorepvec, an oncolytic immunotherapy delivered intravesically

Cretostimogene
grenadenorepvec an
oncolytic immunotherapy (OIT)

Thumbnail of a downloadable image of an NMIBC tumor cross section of the bladder Ta, T1, and CIS

NMIBC tumor cross section of the
bladder Ta,
T1, and CIS

Thumbnail of a downloadable image of cretostimogene instillation in the bladder

Cretostimogene
grenadenorepvec
instillation in the bladder

Thumbnail of a downloadable mechanism of action image of cretostimogene attaching to a CAR receptor

Cretostimogene
grenadenorepvec
attaching to a CAR receptor

Thumbnail of a downloadable image of E2F promoter being permanently activated in cancer cells next to image of healthy cells

E2F promoter is permanently activated in cancer cells: cancer cells and healthy cells

Thumbnail of a downloadable image of cretostimogene grenadenorepvec and a CIS tumor

Cretostimogene grenadenorepvec
and a CIS tumor

Thumbnail of a downloadable image of cretostimogene grenadenorepvec progeny

Cretostimogene grenadenorepvec
progeny

Thumbnail of a downloadable image of cretostimogene grenadenorepvec, an oncolytic immunotherapy inside the bladder

Cretostimogene grenadenorepvec an oncolytic immunotherapy (OIT)

Thumbnail of a downloadable image of cretostimogene grenadenorepvec, an oncolytic immunotherapy (OIT) encoding the granulocyte-macrophage colony stimulating factor, commonly known as GM-CSF

Cretostimogene
grenadenorepvec an
oncolytic immunotherapy (OIT)

Thumbnail of a downloadable image of NMIBC CIS tumor in the bladder

NMIBC CIS tumor in the
bladder

Thumbnail of a downloadable image of additional cretostimogene grenadenorepvec progeny being released

Additional cretostimogene grenadenorepvec progeny being released

Follow CG Oncology on LinkedIn.
Connect Here Connect Here